AB0458 SYSTEMIC TREATMENT IN BEHÇET'S DISEASE ACCORDING TO CLINICAL PHENOTYPES. STUDY OF 111 PATIENTS. (2nd June 2020)

• Record Type: Journal Article
• Authors: Alvarez Reguera, C.; Martínez-López, D.; Sanchez Bilbao, L.; Herrero Morant, A.; Martín-Varillas, J. L.; Suárez Amorín, G.; Setien Preciados, P.; Mata Arnaiz, M. C.; González-Gay, M. Á.; Blanco, R.
• Is Part Of: Annals of the rheumatic diseases. Volume 79(2020)Supplement 1
• Page Start: 1527
• Page End: 1528
• Publication Date: 2020-06-02
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2020-eular.5005
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Behçet's disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and biological immunosuppressants (IS) may also be used. Objectives: To evaluate the systemic treatment of BD according to clinical domains. Methods: Study of all consecutive 111 patients diagnosed with definitive or possible BD by expert rheumatologists in a well-defined population of Northern Spain, between 1980 and 2019. Most of them met the International Criteria for BD (ICBD) (1). Results: We studied 111 patients (62 women/49 men), mean age at diagnosis 36.8±13.2 years. After a mean follow-up of 81.4±85 months, all patients required systemic treatment (TABLE 1 -2). Biological therapy (n=28) was indicated by ocular manifestations (n=13; 46.4%) persistent, severe and refractory oral ulcers (n=10, 35.7%), neurological (n=2; 7.1%), musculoskeletal (n=2; 7.1%) or cutaneous involvement (1; 3.6%). Adalimumab and Infliximab were the biological therapy more frequently used. Conclusion: Most patients with BD required oral corticosteroids and colchicine. Almost half required conventional IS. Up to a third required biologic therapy, especially by ocular involvement. Most patients had clinical improvement. References: [1]Criteria for diagnosis of Behcet's disease, International Study Group for Behçet's Disease, The Lancet, Volume 335, Issue 8697, 1078 – 1080 Disclosure of Interests: Carmen Alvarez Reguera: None declared, David Martínez-López: None declared, Lara Sanchez Bilbao: None declared, Alba Herrero Morant: None declared, José Luis Martín-Varillas Grant/research support from: AbbVie, Pfizer, Janssen and Celgene, Speakers bureau: Pfizer and Lilly, Guillermo Suárez Amorín: None declared, Patricia Setien Preciados: None declared, M. Cristina Mata Arnaiz: None declared, Miguel Á. González-Gay Grant/research support from: AbbVie, MSD and Roche, Speakers bureau: AbbVie, MSD and Roche, Ricardo Blanco Grant/research support from: Abbvie, MSD and Roche, Consultant of: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen and MSD, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Lilly and MSD